Company to Host Conference Call at 8:30am ET Today
DALLAS and FORT WORTH, Texas, March 14, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today reported financial results for the fourth quarter and full year ended December 31, 2016 and provided a business update.
“The strong prescription growth of Adzenys XR-ODT speaks to the growing demand for this first ever extended release ODT treatment option for patients with ADHD, and the success of our launch. Some encouraging trends include approximately 75% of all new prescriptions are coming from patient switches from another ADHD medication and we are seeing utilization across the spectrum of ADHD patients, from pediatric to adolescents and adults,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics. “We are pleased to have recently completed a successful public offering and believe that these additional funds will be instrumental as we prepare for the potential launch of two additional patient-friendly ADHD products in the second half of this year. If approved, Cotempla XR-ODT, our methylphenidate XR-ODT and NT-0201, our amphetamine oral suspension will be launched utilizing our existing sales force and commercial infrastructure and will complement Adzenys XR-ODT. We have a PDUFA goal date of June 19, 2017 for Cotempla XR-ODT and a PDUFA goal date of September 15, 2017 for NT-0201.”
